Discovery of dihydropyridinone derivative as a covalent EZH2 degrader

被引：2

作者：

Zhou, Bin ^{[1
,2
]}

Wang, Beilei ^{[1
,3
,4
]}

Zou, Fengming ^{[1
,3
,4
]}

Mei, Husheng ^{[1
,2
]}

Liu, Qingwang ^{[1
,3
,4
]}

Qi, Shuang ^{[1
,3
,4
,5
]}

Wang, Wenliang ^{[1
,5
]}

Jin, Rui ^{[1
,3
]}

Wang, Aoli ^{[1
,3
,4
]}

Chen, Yongfei ^{[1
,3
,4
]}

Liu, Feiyang ^{[1
,4
,5
]}

Wang, Wenchao ^{[1
,2
,3
,4
,5
]}

Liu, Jing ^{[1
,2
,3
,4
,5
,6
]}

Liu, Qingsong ^{[1
,2
,3
,4
,5
,6
]}

机构：

[1] Chinese Acad Sci, Inst Hlth & Med Technol, Hefei Inst Phys Sci, Anhui Prov Key Lab Med Phys & Technol, Hefei 230031, Anhui, Peoples R China

[2] Univ Sci & Technol China, Hefei 230026, Anhui, Peoples R China

[3] Chinese Acad Sci, Hefei Canc Hosp, Hefei 230031, Anhui, Peoples R China

[4] Precis Med Res Lab Anhui Prov, Hefei 230088, Anhui, Peoples R China

[5] Primary Cell Engn Joint Lab Anhui Prov, Hefei 230088, Anhui, Peoples R China

[6] Chinese Acad Sci, Hefei Inst Phys Sci, Hefei 230031, Anhui, Peoples R China

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2023年 / 261卷

基金：

中国国家自然科学基金;

关键词：

Enhancer of zeste homolog 2; Covalent inhibitor; EZH2; degrader; HISTONE METHYLTRANSFERASE EZH2; LYSINE; 27; POLYCOMB; INHIBITOR; LYMPHOMA; COMPLEX; DESIGN; HYPERTRIMETHYLATION; IDENTIFICATION; METHYLATION;

D O I：

10.1016/j.ejmech.2023.115825

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

EZH2 is overexpressed in multiple types of cancer and high expression level of EZH2 correlates with poor prognosis. Besides the regulation of H3K27 trimethylation, EZH2 itself regulates its downstream proteins in a PRC2-and methylation-independent way. Starting from an approved EZH2 inhibitor EPZ-6438, we used covalent drug design and medicinal chemistry approaches to discover a novel covalent EZH2 degrader 38, which forms a covalent bond with EZH2 Cys663 and showed strong biochemical activities against EZH2 WT and mutants. Compound 38 exhibited potent antiproliferation effects against both B-cell lymphoma and TNBC cell lines by reducing the levels of H3K27me3 and EZH2. The mass spectrometry, washout and competition experiments confirmed the covalent binding of 38 to EZH2. This study demonstrates that covalent EZH2 degraders could provide an opportunity for the development of promising new drug candidates.

引用

页数：23

共 50 条

[1] Discovery of a first-in-class EZH2 selective degrader
Ma, Anqi
Stratikopoulos, Elias
Park, Kwang-Su
Wei, Jieli
Martin, Tiphaine C.
Yang, Xiaobao
Schwarz, Megan
Leshchenko, Violetta
Rialdi, Alexander
Dale, Brandon
Lagana, Alessandro
Guccione, Ernesto
Parekh, Samir
Parsons, Ramon
Jin, Jian
NATURE CHEMICAL BIOLOGY, 2020, 16 (02) : 214 - +
[2] Discovery of a novel, highly potent EZH2 PROTAC degrader for targeting non-canonical oncogenic functions of EZH2
Velez, Julia
Dale, Brandon
Park, Kwang-Su
Kaniskan, H. Umit
Yu, Xufen
Jin, Jian
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2024, 267
[3] Covalent inhibitors of EZH2: Design, synthesis and evaluation
Zhang, Qiangsheng
Chen, Xinyi
Hu, Xi
Duan, Xianjie
Wan, Guoquan
Li, Lu
Feng, Qiang
Zhang, Yiqian
Wang, Ningyu
Yu, Luoting
BIOMEDICINE & PHARMACOTHERAPY, 2022, 147
[4] Discovery and Optimization of Tetramethylpiperidinyl Benzamides as Inhibitors of EZH2
Nasveschuk, Christopher G.
Gagnon, Alexandre
Garapaty-Rao, Shivani
Balasubramanian, Srividya
Campbell, Robert
Lee, Christina
Zhao, Feng
Bergeron, Louise
Cummings, Richard
Trojer, Patrick
Audia, James E.
Albrecht, Brian K.
Harmange, Jean-Christophe P.
ACS MEDICINAL CHEMISTRY LETTERS, 2014, 5 (04): : 378 - 383
[5] Discovery of precision targeting EZH2 degraders for triple-negative breast cancer
Wang, Cheng
Chen, Xinye
Liu, Xingchen
Lu, Dehua
Li, Shang
Qu, Lailiang
Yin, Fucheng
Luo, Heng
Zhang, Yonglei
Luo, Zhongwen
Cui, Ningjie
Kong, Lingyi
Wang, Xiaobing
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, 2022, 238
[6] Dissecting and targeting noncanonical functions of EZH2 in multiple myeloma via an EZH2 degrader
Yu, Xufen
Wang, Jun
Gong, Weida
Ma, Anqi
Shen, Yudao
Zhang, Chengwei
Liu, Xijuan
Cai, Ling
Liu, Jing
Wang, Gang Greg
Jin, Jian
ONCOGENE, 2023, 42 (13) : 994 - 1009
[7] Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2)
Xu, Xin
Chen, Jia
Wang, Guan
Zhang, Xiaojuan
Li, Qiang
Zhou, Xiaobo
Guo, Fengying
Li, Min
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2024, 97
[8] Discovery, design, and synthesis of indole-based EZH2 inhibitors
Gehling, Victor S.
Vaswani, Rishi G.
Nasveschuk, Christopher G.
Duplessis, Martin
Iyer, Priyadarshini
Balasubramanian, Srividya
Zhao, Feng
Good, Andrew C.
Campbell, Robert
Lee, Christina
Dakin, Les A.
Cook, Andrew S.
Gagnon, Alexandre
Harmange, Jean-Christophe
Audia, James E.
Cummings, Richard T.
Normant, Emmanuel
Trojer, Patrick
Albrecht, Brian K.
BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2015, 25 (17) : 3644 - 3649
[9] Discovery of a Novel Covalent EZH2 Inhibitor Based on Tazemetostat Scaffold for the Treatment of Ovarian Cancer
Zhang, Qiangsheng
Chen, Xinyi
Cao, Jiaying
Yang, Wan
Wan, Guoquan
Feng, Qiang
Zhou, Shuyan
Yang, Hongling
Wang, Ningyu
Liu, Zhihao
Xiao, Hongtao
Zhu, Yongxia
Yu, Luoting
JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (03) : 1725 - 1741
[10] Development of secondary mutations in wild-type and mutant EZH2 alleles cooperates to confer resistance to EZH2 inhibitors
Gibaja, V.
Shen, F.
Harari, J.
Korn, J.
Ruddy, D.
Saenz-Vash, V.
Zhai, H.
Rejtar, T.
Paris, C. G.
Yu, Z.
Lira, M.
King, D.
Qi, W.
Keen, N.
Hassan, A. Q.
Chan, H. M.
ONCOGENE, 2016, 35 (05) : 558 - 566

← 1 2 3 4 5 →